Author Affiliations: Departments of Bioimmunotherapy (Drs Kalidas and Talpaz) and Leukemia (Dr Kantarjian), M.D. Anderson Cancer Center, Houston, Tex.
Contempo Updates Section Editors: Alice T.
D. Hughes, MD; Janet M. Torpy, MD, Fishbein Fellows.
Chronic myelogenous leukemia (CML) is a disorder of hematopoietic stem
cells1 accounting for 15% of adult leukemias.
The median age at presentation is between 50 and 60 years; 12% to 30% of patients
at diagnosis are older than 60 years.
Chronic myelogenous leukemia classically progresses through 3 phases,
becoming more resistant to treatment in each successive phase. The majority
of patients present in the chronic phase, which may last 4 to 6 years and
is often asymptomatic at diagnosis. In the accelerated phase, symptoms become
worse and immature blasts increase in the peripheral blood. The duration of
this phase may last as long as a year. The final and fatal blastic phase (>30%
blasts in the bone marrow or peripheral blood) has features of an acute leukemia
including fever, weight loss, bleeding, and anemia; this phase may last 3
to 6 months.
Kalidas M, Kantarjian H, Talpaz M. Chronic Myelogenous Leukemia. JAMA. 2001;286(8):895–898. doi:10.1001/jama.286.8.895
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.